PMID- 25223744
OWN - NLM
STAT- MEDLINE
DCOM- 20150616
LR  - 20211021
IS  - 1699-3055 (Electronic)
IS  - 1699-048X (Print)
IS  - 1699-048X (Linking)
VI  - 16
IP  - 11
DP  - 2014 Nov
TI  - Clinical management of regorafenib in the treatment of patients with advanced 
      colorectal cancer.
PG  - 942-53
LID - 10.1007/s12094-014-1212-8 [doi]
AB  - Colorectal cancer is one of the most common tumors worldwide and at least 50 % of 
      patients with this disease develop metastases. In this setting, additional 
      treatment options are needed for patients presenting disease progression after 
      exhausting all standard therapies. Regorafenib is an orally administered 
      multikinase inhibitor which has been shown to provide survival benefits to 
      patients with metastatic colorectal cancer (mCRC). Although most adverse events 
      (AEs) associated with regorafenib may resolve within the first 8 weeks of 
      treatment, some of them may require dose reduction or treatment interruption. 
      Overall, while remaining aware of the safety profile of regorafenib and how to 
      manage the most common toxicities related to its use, this drug should be 
      considered a new standard of care for patients with pretreated mCRC. This review 
      addresses practical aspects of its use, such as dosing, patient monitoring, and 
      management of the most common regorafenib-related AEs.
FAU - Sastre, J
AU  - Sastre J
AD  - Medical Oncology Department, Clinic San Carlos University Hospital (Center 
      Affiliated with the Red Tematica de Investigacion Cooperativa en Cancer, 
      Instituto Carlos III, Spanish Ministry of Science and Innovation), Calle Profesor 
      Martin Lagos, s/n, 28040, Madrid, Spain, jsastrev@salud.madrid.org.
FAU - Argiles, G
AU  - Argiles G
FAU - Benavides, M
AU  - Benavides M
FAU - Feliu, J
AU  - Feliu J
FAU - Garcia-Alfonso, P
AU  - Garcia-Alfonso P
FAU - Garcia-Carbonero, R
AU  - Garcia-Carbonero R
FAU - Gravalos, C
AU  - Gravalos C
FAU - Guillen-Ponce, C
AU  - Guillen-Ponce C
FAU - Martinez-Villacampa, M
AU  - Martinez-Villacampa M
FAU - Pericay, C
AU  - Pericay C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140916
PL  - Italy
TA  - Clin Transl Oncol
JT  - Clinical & translational oncology : official publication of the Federation of 
      Spanish Oncology Societies and of the National Cancer Institute of Mexico
JID - 101247119
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 24T2A1DOYB (regorafenib)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Colorectal Neoplasms/*drug therapy
MH  - Humans
MH  - Phenylurea Compounds/*therapeutic use
MH  - Pyridines/*therapeutic use
PMC - PMC4194027
EDAT- 2014/09/17 06:00
MHDA- 2015/06/17 06:00
PMCR- 2014/09/16
CRDT- 2014/09/17 06:00
PHST- 2014/07/29 00:00 [received]
PHST- 2014/08/01 00:00 [accepted]
PHST- 2014/09/17 06:00 [entrez]
PHST- 2014/09/17 06:00 [pubmed]
PHST- 2015/06/17 06:00 [medline]
PHST- 2014/09/16 00:00 [pmc-release]
AID - 1212 [pii]
AID - 10.1007/s12094-014-1212-8 [doi]
PST - ppublish
SO  - Clin Transl Oncol. 2014 Nov;16(11):942-53. doi: 10.1007/s12094-014-1212-8. Epub 
      2014 Sep 16.